What's Next: CKD in People with Diabetes—A Case-Based Discussion
DOC Updates

What's Next: CKD in People with Diabetes—A Case-Based Discussion

Nov 3, 2026
42:49
-(0)

About this episode

There are multiple options now for slowing the progression of chronic kidney disease. In part 5 of our special series, host Dr. Neil Skolnik takes a case-based approach to explore treatment options for CKD. This special episode is sponsored with support from Bayer . Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Holly Kramer , MD, MPH, Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, Illinois Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 doi.org/10.2337/dc26-S011 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 doi.org/10.1056/NEJMoa2025845 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 doi.org/10.1056/NEJMoa2024816 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 doi.org/10.1056/NEJMoa2403347 Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023;46(9):1574–1586 doi.org/10.2337/dci23-0030 The Kidney Failure Risk Equation - kidneyfailurerisk.com

Comments

Rate this episode

Episode Details

Show Type
full
Audio Format
audio/mpeg

We use analytics

We use Umami, a privacy-friendly analytics tool, to understand how visitors use this site. No personal data is collected and no data leaves our EU servers. You can accept or decline below. Privacy Policy